Potent and Prolonged Hypoglycemic Activity of an Oral Insulin – Tat Mixture in Diabetic Mice

 

 Buy Article Permissions and Reprints

Abstract

Trans-activator of transcription (Tat) is a cell penetrating peptide which can translocate and carry macromolecular cargoes through cell membranes. This study investigated the hypoglycemic activity of orally delivered insulin – Tat mixture in alloxan-induced diabetic mice. The mixtures of insulin and Tat at 1:1, 1:3 and 1:6 molar ratios were given orally at the insulin doses ranging from 1–200 IU/kg. The fasting blood glucose (FBG) levels were measured at initial, 1, 2, 4, 6, and 12 h after administration. At 1:3 molar ratio of the mixture and after 12 h of administration, insulin at 200 IU/kg showed the highest with prolonged hypoglycemic activity of 74.0±10.3% FBG reduction (2.18 folds of subcutaneously injected (SC) insulin). Free insulin administered orally did not show any hypoglycemic activity. The mixtures at the insulin doses of 100 and 50 IU/kg also showed potent FBG reduction of 73.8±8.2 and 71.3±16.9% at 12 h after administration (2.18 and 2.10 folds of SC insulin, respectively). After incubation with Mono-Mac-6 cells, only the ­mixtures but not the free insulin showed intra­cellular insulin uptake, indicating the insulin penetration through the cell membranes via Tat. In simulated gastric fluid, the insulin content in the mixture was not found, demonstrating the degradation of insulin in the gastric environments. Insulin may be absorbed at upper gastrointestinal tract facilitated by Tat. The potent and prolonged hypoglycemic activity of insulin co-administered orally with Tat can be further developed as an effective oral insulin delivery system.

• References

• 1 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14
  CrossrefPubMedGoogle Scholar
• 2 World Health Organization . Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: 1999. Report No.: WHO/NCD/NCS/992
  Google Scholar
• 3 Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?. Clin Diabetes 2009; 27: 60-68
  CrossrefPubMedGoogle Scholar
• 4 Snow EK. (ed.). AHFS Drug Information 2009. Bethesda (MD): American Society of Health – System Pharmacists; 2009
• 5 Heller S, Kozlovski P, Kurtzhals P. Insulin’s 85^th anniversary – an enduring medical miracle. Diabetes Res Clin Pract 2007; 78: 149-158
  CrossrefPubMedGoogle Scholar
• 6 Khafagy E-S, Morishita M, Onuki Y et al. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliver Rev 2007; 59: 1521-1546
  CrossrefPubMedGoogle Scholar
• 7 Hansen M, Kilk K, Langel Ü. Predicting cell-penetrating peptides. Adv Drug Deliver Rev 2008; 60: 572-579
  CrossrefPubMedGoogle Scholar
• 8 Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliver Rev 2009; 61: 953-964
  CrossrefPubMedGoogle Scholar
• 9 Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliver Rev 2005; 57: 637-651
  CrossrefPubMedGoogle Scholar
• 10 Brooks H, Lebleu B, Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliver Rev 2005; 57: 559-577
  CrossrefPubMedGoogle Scholar
• 11 Liang JF, Yang VC. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 2005; 335: 734-738
  CrossrefPubMedGoogle Scholar
• 12 Tangjai T, Manosaroi A, Werner RG et al. Hypoglycemic effect improvement of oral human insulin by conjugating with Tat peptide. The Third International Conference on Natural Products for Health and Beauty 2011 Bangkok, Thailand
  PubMedGoogle Scholar
• 13 Deshayes S, Morris M, Heitz F et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliver Rev 2008; 60: 537-547
  CrossrefPubMedGoogle Scholar
• 14 Lohcharoenkal W, Manosaroi A, Götz F et al. Potent enhancement of GFP uptake into HT-29 cells and rat skin permeation by coincubation with Tat peptide. J Pharm Sci 2011; 100: 4766-4773
  CrossrefPubMedGoogle Scholar
• 15 Manosroi J, Moses ZZ, Manosroi W et al. Hypoglycemic activity of Thai medicinal plants selected from the Thai/Lanna Medicinal Recipe Database MANOSROI II. J Ethnopharmacol 2011; 138: 92-98
  CrossrefPubMedGoogle Scholar
• 16 Sun J-E, Ao Z-H, Lu Z-M et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol 2008; 118: 7-13
  CrossrefPubMedGoogle Scholar
• 17 Christensen SD, Mikkelsen LF, Fels JJ et al. Quality of plasma sampled by different methods for multiple blood sampling in mice. Lab Anim 2009; 43: 65-71
  CrossrefPubMedGoogle Scholar
• 18 The United States Pharmacopeial Convention . United States Pharmacopeia (USP) 34 – National Formulary (NF) 29. Rockville (MD): The Convention; 2011
  Google Scholar
• 19 Win PP, Shin-ya Y, Hong K-J et al. Effect of proteolytic enzymes in gastrointestinal fluids on drug release from polyelectrolyte complex microspheres based on partially phosphorylated chitosan. Polym Int 2005; 54: 533-536
  CrossrefPubMedGoogle Scholar
• 20 Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci 2011; 42: 445-451
  CrossrefPubMedGoogle Scholar
• 21 Hu J-W, Liu BR, Wu C-Y et al. Protein transport in human cells mediated by covalently and noncovalently conjugated arginine-rich intracellular delivery peptides. Peptides 2009; 30: 1669-1678
  CrossrefPubMedGoogle Scholar
• 22 Khafagy E-S, Morishita M, Isowa K et al. Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release 2009; 133: 103-108
  CrossrefPubMedGoogle Scholar
• 23 Lu S-W, Hu J-W, Liu BR et al. Arginine-rich intracellular delivery peptides synchronously deliver covalently and noncovalently linked proteins into plant cells. J Agr Food Chem 2010; 58: 2288-2294
  CrossrefPubMedGoogle Scholar
• 24 Lambert DG. Drugs and receptors. CEACCP 2004; 4: 181-184
  PubMedGoogle Scholar
• 25 Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100: 4162-4167
  CrossrefPubMedGoogle Scholar
• 26 Mishra A, Lai GH, Schmidt NW et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci USA 2011; 108: 16883-16888
  CrossrefPubMedGoogle Scholar
• 27 Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16: 351-380
  CrossrefPubMedGoogle Scholar
• 28 El-Andaloussi S, Järver P, Johansson H et al. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 2007; 407: 285-292
  CrossrefPubMedGoogle Scholar
• 29 Saar K, Lindgren M, Hansen M et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem 2005; 345: 55-65
  CrossrefPubMedGoogle Scholar

• Supplementary Material